$7.97
1.60% day before yesterday
Nasdaq, Dec 26, 10:00 pm CET
ISIN
US35104E1001
Symbol
FDMT

4D Molecular Therapeutics Inc Stock price

$7.97
-3.02 27.48% 1M
+3.90 95.82% 6M
+2.40 43.09% YTD
+2.16 37.18% 1Y
-13.62 63.08% 3Y
-35.00 81.45% 5Y
-15.03 65.35% 10Y
-15.03 65.35% 20Y
Nasdaq, Closing price Fri, Dec 26 2025
-0.13 1.60%
ISIN
US35104E1001
Symbol
FDMT
Industry

Key metrics

Basic
Market capitalization
$455.4m
Enterprise Value
$150.3m
Net debt
positive
Cash
$305.1m
Shares outstanding
46.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
3,794.7 | 57.8
EV/Sales
1,252.6 | 19.1
EV/FCF
negative
P/B
1.2
Financial Health
Equity Ratio
91.1%
Return on Equity
-31.5%
ROCE
-59.6%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$120.0k | $7.9m
EBITDA
$-227.2m | $-213.3m
EBIT
$-230.4m | $-215.6m
Net Income
$-209.2m | $-175.4m
Free Cash Flow
$-185.1m
Growth (TTM | estimate)
Revenue
-99.4% | 19,585.0%
EBITDA
4.8% | -16.4%
EBIT
5.8% | -14.8%
Net Income
1.3% | -9.0%
Free Cash Flow
-58.5%
Margin (TTM | estimate)
Gross
-
EBITDA
-189,307.5% | -2,709.0%
EBIT
-191,982.5%
Net
-174,314.2% | -2,227.8%
Free Cash Flow
-154,209.2%
More
EPS
$-3.7
FCF per Share
$-4.0
Short interest
9.1%
Employees
227
Rev per Employee
$0.0
Show more

Is 4D Molecular Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

4D Molecular Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a 4D Molecular Therapeutics Inc forecast:

14x Buy
82%
3x Hold
18%

Analyst Opinions

17 Analysts have issued a 4D Molecular Therapeutics Inc forecast:

Buy
82%
Hold
18%

Financial data from 4D Molecular Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
0.12 0.12
99% 99%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 49 49
30% 30%
41,100%
- Research and Development Expense 181 181
7% 7%
150,983%
-227 -227
5% 5%
-189,308%
- Depreciation and Amortization 3.21 3.21
47% 47%
2,675%
EBIT (Operating Income) EBIT -230 -230
6% 6%
-191,983%
Net Profit -209 -209
1% 1%
-174,317%

In millions USD.

Don't miss a Thing! We will send you all news about 4D Molecular Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

4D Molecular Therapeutics Inc Stock News

Neutral
Seeking Alpha
10 days ago
4D Molecular Therapeutics, Inc. (FDMT) Discusses Interim Phase I Data From AEROW Trial in Cystic Fibrosis and Platform Potential Transcript
Neutral
GlobeNewsWire
10 days ago
Clinically meaningful lung function activity, measured by ppFEV 1 and LCI 2.5 , with follow-up through 1 year at dose selected for Phase 2  Durable CFTR transgene expression within target therapeutic range with follow-up through at least 1 year Data support 4D-710's potential to be a durable, redosable, variant-agnostic, disease-modifying treatment for people with cystic fibrosis lung disease w...
Neutral
GlobeNewsWire
15 days ago
EMERYVILLE, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on December 9, 2025, the compensation committee of the Company's boa...
More 4D Molecular Therapeutics Inc News

Company Profile

4D Molecular Therapeutics, Inc. engages in the design, development, and commercialization of transformative gene therapeutic products for serious unmet medical conditions. It offers products for optalmology, cardiology, and pulmonology. The company was founded by David H. Kirn, Melissa Kotterman, Theresa Janke, and David Schaffer on September 12, 2013 and is headquartered in Emeryville, CA.

Head office United States
CEO David Kirn
Employees 227
Founded 2013
Website 4dmoleculartherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today